To date, several prognostic biomarkers have been investigated in localized GIST besides RTKs (KIT, PDGFRA), such as cyclin-dependent kinase inhibitor 2A (CDKN2A/p16), aurora kinase A (AURKA), neurofibromatosis type 2 (NF2), histone modifier gene SET domain containing 2 (SETD2), Raf kinase inhibitor protein (RKIP), potassium channel tetramerization domain containing protein 10 (KCTD10), SLIT and NTRK-like family member 3 (SLITRK3), or orphan receptor 2 (ROR2).31 However, these prognostic biomarkers were mainly issued from studies with limited sample size. This evidence concerns the gene AURKA and gastrointestinal stromal tumor.